Age per 10 years | 0.81 (0.54–1.22) | 0.315 | | |
Male sex | 1.55 (0.35–6.83) | 0.256 | | |
SLE | 0.87 (0.33–2.3) | 0.777 | | |
WHO FC III/IV | 2.73 (0.91–8.20) | 0.074 | | |
6MWD per 100 m | 0.61 (0.38–0.99) | 0.045 | | |
RVDD on TTE per10 mm | 1.10 (0.71–1.70) | 0.661 | | |
PCE on TTE | 3.31 (1.18–9.26) | 0.023 | | |
FVC per 10% predicted | 0.93 (0.59–1.48) | 0.771 | | |
DLCO per 10% predicted | 0.80 (0.18–3.65) | 0.776 | | |
FVC/DLCO per 0.1 | 1.09 (0.48–2.53) | 0.833 | | |
mRAP per 5 mmHg | 1.19 (0.74–1.91) | 0.484 | | |
mPAP per 10 mmHg | 1.16 (0.90–1.49) | 0.264 | | |
Cardiac index per 1 L·min−1·m−2 | 0.58 (0.32–1.05) | 0.073 | | |
PVR per 3 Wood units | 1.27 (1.08–1.49) | 0.003 | 1.34 (1.04–1.73) | 0.023 |
SvO2 per 10% | 0.63 (0.43–0.91) | 0.014 | | |
UA per 100 μmol·L−1 | 1.29 (0.91–1.85) | 0.156 | | |
TBil per 10 μmol·L−1 | 1.32 (0.96–1.84) | 0.088 | | |
TC per 1 mmol·L−1 | 0.61 (0.40–0.93) | 0.021 | | |
ALP per 50 IU·L−1 | 1.72 (1.15–2.58) | 0.009 | 1.72 (1.01–2.93) | 0.045 |
Anti-U1 RNP | 1.64 (0.57–4.7) | 0.361 | | |
PAH-targeted therapy | 0.353 (0.05–2.68) | 0.313 | | |
Immunosuppressive therapy | 0.89 (0.21–3.86) | 0.874 | | |